Kornimate/medical-research-clean huggingface dataset:
study of natural killer cells in patients with metastatic prostate cancer: relationship with survival and response time to castration

Conditions: Metastatic Prostate Cancer

Summary: prospective research of natural killer cells as predictive biomarkers to stratify patients likely to have longer response time to castration.

the main objective is to validate prospectively the results of a retrospective study showing a correlation between the level of nkp30 and nkp46 receptor-activators expression on the surface of nk cells and 1) the survival time, 2) the response time to castration in patients with metastatic prostate cancer. prospective monocenter, open-label study. during a visit in the frame of management of the disease, a single blood sample will be collected. patients will then have a standard care follow-up for a period of 5 years. follow up data (death, progression) will be collected every 6 months.

Eligibility criteria:
inclusion criteria: 1. patient with metastatic prostate cancer. 2. aged of 18 years or more. 3. patient in period of sensitivity to castration (patient non castrated or castration performed less than 1 year ago) and lack of progression. 4. patient having signed an informed consent. 5. patient affiliated to the national "social security" regimen or beneficiary of this regimen. exclusion criteria: 1. patient under chemotherapy treatment at the time of sampling 2. patient under corticotherapy treatment at the time of sampling 3. patient in emergency situation, adult subject to a measure of legal protection (placed under judicial protection, tutorship, or curatorship), or unable to give consent. 4. any psychological, familial, sociological or geographical condition potentially hampering compliance with the study medical follow-up 5. contraindications to study procedure

Keywords: prostate, metastatic
comparative evaluation of irm and autopsy in the evaluation of intra uterine fetal death

Conditions: Spontaneous Intra Uterine Fetal Death

Summary: fetal intra uterine death is a rare event (incidence 2/1000 births) , unexpected and psychologically painful for the couple and the healthcare team. in this difficult context, it is essential to understand the etiology of death to guide the management of subsequent pregnancies. among the investigations, foetopathologic examination is essential, but the examination of the brain is not possible in more than half of the cases due to the cerebral maceration due to the incompressible delay between death and expulsion. the use of mri as a diagnostic tool fetal post- mortem " virtual autopsy " performed before expulsion of the fetus is interesting because it would permit to obtain a macroscopic examination of the fetal brain, archivable, and a gain concerning the diagnosis. thus, a normal mri will exclude cerebral anatomical abnormality , stroke or bleeding . if mri abnormalities are found , it will not only guide the foetopathologic review, but mainly to guide the etiology . on the other hand , it is a non-invasive tool and acceptability by the couple would be better than autopsy which is often refused by the couple in this difficult psychological context. in this study , mri will be given in addition to conventional autopsy in the painful waiting time between the time of diagnosis of death and expulsion without delaying care . if this study is validated , mri may be systematically proposed in this indication or alternative to autopsy when it will be refused by the parents.


Eligibility criteria:
inclusion criteria: * patient for which he was diagnosed with intra uterine death confirmed by ultrasound * mono fetal pregnancy, * term: 24 to 42 weeks' gestation * age\> 18 years * patient having readen the letter of information and signed the consent. exclusion criteria: * contraindication to mri (heart valve, pacemaker, neurosurgical clips, claustrophobia, intraocular metallic foreign bodies) * maternal complications: bleeding during, eclampsia, placental hematoma retro, imminent work * twin pregnancy * patient under guardianship or trusteeship * patient not speaking and writing french

Keywords: spontaneous intrauterine death fetal mri autopsy
regulation of inflammatory genes in psoriasis

Conditions: Psoriasis; Inflammation

Summary: psoriasis is a chronic and recurrent skin disorder characterized by marked inflammatory changes in the skin. an extensive cytokine network including generated by activated dendritic cells and t cells mediates the formation of psoriatic lesions. these immune-response parameters can be used as markers in the severity and management of the disease after further in-depth studies.


Eligibility criteria:
inclusion criteria: * clinical diagnosis of psoriasis * must be age 19 or older. * must be fitzpatrick skin type i, ii, iii, iv, v, vi. exclusion criteria: * subjects who do not have photosensitive disease and are not on photosensitizing medications. * subjects with a history of keloids (who are more likely to develop hypertrophic scars following skin biopsy). * subjects who have an allergy to local anesthetics, antibiotics and/or anticoagulants. * subjects who are pregnant.

Keywords: cytokines
the american glaucoma society (ags) second aqueous shunt implant vs. transscleral cyclophotocoagulation treatment study (assists)

Conditions: Glaucoma

Summary: outcomes of subjects with uncontrolled glaucoma with a single existing aqueous tube shunt implant undergoing a second aqueous shunt to transscleral diode laser cyclophotocoagulation.

this is a study comparing short- (1 year), mid- (3 years), and long-term (5 years) cumulative incidences of failures in participants who undergo a second aqueous shunt (sas) to those cumulative incidences of failures in participants who undergo a second aqueous shunt (sas) to those cumulative incidences of failures in participants who undergo transscleral diode laser cyclophotocoagulation (tlc) for eyes with uncontrolled glaucoma with a single existing aqueous tube shunt procedure.

Eligibility criteria:
inclusion criteria: * women and men 18 to 85 years of age * glaucoma not adequately controlled (iop \>18 mmhg on maximum tolerated topical therapy) with a single aqueous shunt (as). * best-corrected visual acuity (bcva) of hand motion (hm) or better in the study eye exclusion criteria: * monocular * presence of more than one as in the study eye * previous cyclodestruction in the study eye * presence of active iris neovascularization in the study eye * binocular diplopia * presence of scleral buckle in the study eye * history or scleritis in either eye * history of scleromalacia in the study eye * insufficient conjunctiva to cover as in the study eye * iop cannot be accurately measured with goldmann applanation, pneumotonometry, or tono-pen in the study eye * presence of silicone oil in the study eye * presence of retinal detachment in the study eye * presence of intraocular or orbital tumor affecting the study eye * need for cataract extraction or concurrent procedure at the time of study treatment, except tectonic aqueous shunt revisions for both groups is allowed. * in the opinion of the investigator, should not be enrolled in this study * unwilling or unable to give consent and satisfy requirements of the study
hyperfractionated rt with bcnu versus conventional rt with bcnu for supratentorial malignant glioma

Conditions: Glioma; Glioblastoma Multiforme; Astrocytoma

Summary: hyperfractionated radiation therapy (rt) to 72.0 gy with bcnu will be compared to conventional radiation therapy to 60.0 gy with bcnu to determine if hyperfractionated rt can improve the median survival time of adults with supratentorial malignant gliomas.


Eligibility criteria:
inclusion criteria: * histopathologically confirmed glioblastoma multiforme (with areas of necrosis), malignant astrocytoma and astrocytoma with foci of anaplasia * karnofsky performance score ≥ 60 * absolute neutrophil count ≥ 1,500 * platelets ≥ 100,000 * bun ≤ 25 * creatinine ≤ 1.5 * bilirubin ≤ 2.0 * hemoglobin ≥ 10 gm * sgot \< 2 x upper limit of normal * sgpt \< 2 x upper limit of normal exclusion criteria: * no prior radiation to the head or neck area, chemotherapy or radiosensitizer * no malignancy with the past five years except non-melanomatous skin cancer or carcinoma in-situ of the cervix

Keywords: glioma glioblastoma glioblastoma multiforme astrocytoma
slow myopia progression with different irradiance light

Conditions: Myopia, Progressive

Summary: it is a prospective clinical control study on red light control myopia with specail design spectacles for 75 children in 3 groups. study groups with two different powers of 0.6 mw and 1.2 mw at wavelength of 650nm. the control group is to wear the same brand and design spectalces as those two study groups. in addition, the progression of myopia is usually accompanied by the changes in a variety of ocular parameters, such as refractive error, reduced submacular choroidal thickness, and prolonged length of the ocular axis length.the goal is to test which power (1.2mw and 0.6mw) is better in myopic children for 3 month's follow-up and also to test how to get better result with the increaing or decreasing lighting power for the total 6 month follow-up results .

it is a prospective clinical control study on red light control myopia with specail design spectacles for 75 children in 3 groups. each group has 25 myopic children. study groups with two different powers of 0.6 mw and 1.2 mw at wavelength of 650nm are randomized to be allocated into the 3 groups. the control group is to wear the same brand and design spectalces as those two study groups. in addition, the progression of myopia is usually accompanied by the changes in a variety of ocular parameters, such as refractive error, reduced submacular choroidal thickness, and prolonged length of the ocular axis length. all groups will be wearing a special lens named by stellest with high aspherical lens design.

Eligibility criteria:
inclusion criteria: * 6\~12 years old * refractive error of myopia within -0.50 d\~-5.00 d, anisometropia less or equal to 2.00d, the best corrected vision acuity is better or equal to 0.8 （decimal record). * written consent formed with supervisions and children with 6 month follow-up. exclusion criteria: * photophobia or allergy to any cycloplegic eyedrops (such as tropcaine, cyclopentolate). * lesions in fundus or any part of eyeball with abnormal corrected vision such as keratoconus. * strabisumus with angles large or equal to 5 prism dioper. * with other myopia control device such as atropine, orthokeratology, misight lens or other myopia control device.
zevalin® first line in follicular lymphoma

Conditions: Follicular Lymphoma

Summary: this is a european multicenter study of 90yttrium-ibritumomab tiuxetan (90y-ibritumomab tiuxetan) (zevalin®) as a front line therapy for patients with follicular lymphoma grade i-iiia and stage iii-iv (as well as for selected patients with extended abdominal stage ii). for patients with complete clinical remission but persistent molecular disease subsequent to 90y-ibritumomab tiuxetan treatment a consolidation immunotherapy with rituximab is added, to eradicate minimal residual disease.

only patients requiring treatment (b-symptoms, lymphoma progression \> 50% within an observation period of 6 months or less, organ compression by lymphoma or bulky disease as defined by lesions above 5 cm on one axis) may enter the study.

Eligibility criteria:
inclusion criteria: * patient \> 50 years old * follicular lymphoma grade i, ii, or iiia according to real/who classification * ann arbor stage iii, or iv, or stage ii with disseminated abdominal disease requiring extensive abdominal irradiation * no prior chemotherapy, immunotherapy, or irradiation. furthermore, when receiving therapy as part of this "zevalin® first line in follicular lymphoma" trial and up to six months after therapy has ended, patients may not participate in another clinical trial. if patients receive consolidation therapy with rituximab, the six months period is counted from the end of the consolidation therapy. * lymphoma cells positive for cd20 * measurable disease (two perpendicular diameters by either physical or radiological examination) * who/ecog performance status 0 - 2 * written informed consent exclusion criteria: * bone marrow involvement only * bone marrow infiltration \> 25% * leukocytopenia \< 2.500 /µl * thrombocytopenia \< 100.000 /µl * bulk lesions \> 10 cm * cns lymphoma manifestation * circulating tumor cells \> 500 /µl * extensive pleural effusion/ascites (\> 1000 ml as estimated by ultrasound/ct) * severe concomitant diseases (e.g. congestive heart failure, myocardial infarction within 6 months of study, severe uncontrolled hypertension, renal insufficiency requiring hemodialysis, pulmonary disease, liver disease) * abnormal liver function: transaminases or total bilirubin \> 2 x upper limit of normal (uln) (unless caused by the lymphoma) * abnormal renal function: serum creatinine \> 2 x upper limit of normal (unless caused by the lymphoma) * previous malignancy other than non-melanoma skin cancer * pregnant or breast feeding female patients (negative pregnancy test required for women of fertile age), no effective contraception * hiv positivity * known hypersensitivity to foreign proteins, murine antibodies, presence of human anti-murine antibodies (hama) reactivity * severe psychiatric illness

Keywords: follicular lymphoma first line therapy zevalin 90yttrium-ibritumomab tiuxetan yttrium rituximab radio-immuno therapy
straberi epistamp device for postinflammatory hyperpigmentation

Conditions: Postinflammatory Hyperpigmentation

Summary: this pilot study will expand knowledge and application needling using the straberi device for the improvement of postinflammatory hyperpigmentation (pih) caused by acne.

this pilot study will expand the knowledge and application of needling using the straberi epistamp device and its safety and benefits for improving the appearance of postinflammatory hyperpigmentation. postinflammatory hyperpigmentation (pih) caused by acne is a common inflammatory disease that can adversely affect facial appearance. facial acne can have a serious negative impact on psychosocial functioning leaving deep emotional scars. severe acne can also lead to physical scars and disfigurement. among patients with severe acne, facial scarring affects both genders equally and occurs to some degree in 95% of cases.

Eligibility criteria:
inclusion criteria: * derma scan showing aging including skin texture, wrinkles, brown spots, and pores. * patients willing to sign informed consent. * patients willing to be photographed and video documented * patients willing to consent to 3 months of treatment exclusion criteria: * history of eczema in the treatment area; psoriasis and any other chronic skin conditions * history of actinic (solar) keratosis in the treatment area; * history of hemophilia * history of diabetes * the presence of raised moles, warts on the targeted area. * collagen vascular diseases or cardiac abnormalities * blood clotting problems * active bacterial or fungal infection * facial melanosis * malignant tumors * immunosuppression * use of blood thinners or prednisone * corticosteroids within two weeks of the procedure * chronic liver disease * porphyria or other skin diseases. * patient not willing to sign informed consent. * tca peels in the last 5 weeks * subject currently has moderate to severe acne on the face. * microneedling within the last 6 months * subject has an active infection. * subject has a history of a bleeding disorder * subject has a history of keloidal tendency * subject has received ablative or non-ablative laser treatments in the previous 6 months. * subject has taken accutane within the previous 3 months.

Keywords: needling postinflammatory hyperpigmentation epistamp universal skincare institute
comparative study between botulinum toxin-a injection and shock waves on hypertrophic scars in hand-burned children

Conditions: Hand-burned Children

Summary: purpose: the study aims to compare study between botulinum toxin-a injection and shock waves therapy on hypertrophic scars in hand-burned children. background: burn injuries can cause significant physical and psychological distress, especially when they result in hypertrophic scarring. in children, who are particularly vulnerable to these injuries, it is important to accurately assess the severity of these scars and their impact on functionality. hypotheses: there is no significant difference between the combined effect of the traditional physical therapy program with botulinum toxin-a injection and the traditional physical therapy program with shock waves therapy on improving wrist extension, ulnar deviation, radial deviation, hand grip strength, and severity of the scar on hypertrophic scars in hand-burned children.


Eligibility criteria:
inclusion criteria: * age will range from 6-18 years * diagnosed with hypertrophic scars resulting from hand burns. * has burn injuries caused by flame, scald or chemical agents. * with a total body surface area (tbsa) varied from 10 to 30% * a resistant partial or complete loss of wrist flexion attributable to wrist flexor contracture * after wound and skin graft healing (\~ 90 days post-surgery), exclusion criteria: * children with underlying medical conditions that could interfere with scar healing or treatment outcomes * skin flap surgery, malignancies, cardiac arrhythmias, pacemaker implantation, coagulopathies, fractures about the treatment area, articular adhesions, and psychiatric co-morbidities
magnetic resonance imaging evaluation of the tissular oxygen saturation in brain

Conditions: Cerebral Tumor; Stroke

Summary: the purpose of this study is to measure the tissular oxygen saturation in brain by magnetic resonance imaging on subjects and to correlate the results with near infrared spectroscopy measurements.


Eligibility criteria:
inclusion criteria: * healthy volunteers or patients with cerebral lesion exclusion criteria: * claustrophobia * mri exclusion criteria

Keywords: mri oxygenation nirs
safety, reactogenicity and immunogenicity of vi-dt;typhoid conjugate vaccine

Conditions: Typhoid

Summary: this is a randomized, observer-blinded phase 2 study in healthy infants and toddlers 6-23 months of age at the time of the first vaccine dose. the purpose of this study is to assess the safety and immunogenicity of the vi-dt vaccine in age group 6-23months of age. the vi-dt vaccine is administered at 25 µg either as a single dose, or two doses given 6 months apart.

this study is carried out in healthy children aged 6 to 23 months at a single site. a total of 285 participants are enrolled, 114, 114 and 57 participants are randomized to either the single dose, two-dose vi-dt regimens or placebo/comparator group, respectively within age strata. three age strata is 6 to less than 9 months, 9 to 12 months and 13 to 23 months. the investigators allow the 9-12 months old children to receive measles-mumps-rubella (mmr) vaccine concomitantly with vi-dt vaccine and descriptive analysis of immune response to mmr only and to mmr and vi-dt vaccines are performed to assess the possible immunological interference with mmr vaccine.

Eligibility criteria:
inclusion criteria: * healthy infants and children 6-23 months of age at enrollment as determined by medical history, physical examination and clinical judgment of the investigator * birth weight ≥ 2500 g * ≥ 37 weeks of pregnancy or judge to be full-term by the midwife or birth attendant * parents aged 18 years and above and legal guardians aged 21 years and above as per the legal authorization in the philippines, who have voluntarily given informed consent * parents/ legal guardians willing to follow the study procedures of the study and available for the entire duration of the study exclusion criteria: * child with a congenital abnormality * subject with abnormal routine biological values at screening * subject concomitantly enrolled or scheduled to be enrolled in another trial * acute illness, in particular infectious disease or fever (axillary temperature ≥37.5°c), within three days prior to enrolment and vaccination * known history of immune function disorders including immunodeficiency diseases, or chronic use of systemic steroids (\>20 mg/day prednisone equivalent for periods exceeding 10 days), cytotoxic or other immunosuppressive drugs * child with a previously ascertained or suspected disease caused by s. typhi * child who have had household contact with/and or intimate exposure to an individual with laboratory-confirmed s. typhi * known history or allergy to vaccines or other medications * know history of allergy to eggs, chicken protein, neomycin and formaldehyde * history of uncontrolled coagulopathy or blood disorders * mother has known hiv infection or other immune function disorders * any abnormality or chronic disease which in the opinion of the investigator might be detrimental for the safety of the subject and interfere with the assessment of the study objectives * child whose parents or legal guardian planning to move from the study area before the end of study period

Keywords: typhoid vi-dt conjugate vaccine first in human new vaccine
a study for patients with acute leukemia

Conditions: Acute Leukemia

Summary: this study is a multicenter, nonrandomized, open-label, dose-escalation with intra-patient dose-escalation, phase 1 study of intravenous ly2523355 to determine the dose of ly2523355 that can be safely administered to participants with acute leukemia. part a and part b are dose escalation of two schedules in participants with acute leukemia. parts a and b will enroll concurrently. part c is a dose expansion for each schedule in participants with acute myeloblastic leukemia (aml).


Eligibility criteria:
inclusion criteria: dose escalation period for both schedules: * participants must have a confirmed diagnosis of acute leukemia regardless of sub-type and for whom experimental phase 1 therapy is appropriate. * are greater than or equal to 18 years of age. * have a performance status of 0 or 1 on the eastern cooperative oncology group (ecog) scale. * females with childbearing potential must have had a negative urine or serum pregnancy test less than or equal to 7 days prior to the first dose of study drug. dose confirmation period for both schedules: * participant must have a confirmed diagnosis of untreated acute myeloblastic leukemia (aml), should not be a candidate for standard therapy, and a clinical trial is a preferred treatment option or have acute aml that is relapsed or refractory to no more than 2 prior induction regimens. hydroxyurea to control prior blast counts is not considered a prior regimen. * are greater than or equal to 60 years of age. * have a performance status of 0 or 1 on the ecog scale. * females with childbearing potential must have had a negative urine or serum pregnancy test less than or equal to 7 days prior to the first dose of study drug. exclusion criteria: * have received treatment within 28 days of the initial dose of study drug with a drug that has not received regulatory approval for any indication. * participants with known central nervous system (cns) leukemia by spinal fluid cytology or imaging. a lumbar puncture is not required unless cns involvement is clinically suspected. participants with signs or symptoms of leukemic meningitis or a history of leukemic meningitis must have a negative lumbar puncture within 2 weeks of study enrollment. * have other active malignancy (with the exception of basal and squamous cell skin cancer) at time of study entry. * have had an autologous or allogenic bone marrow transplant within 3 months. all organ toxicity must be resolved. * have evidence of graft-versus-host disease due to an allogenic bone marrow transplant. * have uncontrolled systemic infection. * females who are pregnant or lactating. * have known positive test results in human immunodeficiency virus (hiv), hepatitis b surface antigen (hbsag), or hepatitis c antibodies (hcab) (screening not required).

Keywords: acute myelogenous leukemia acute lymphoblastic leukemia chronic myelogenous leukemia,blast crisis